We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

The Standard Concentration of Morphine as a Positive Control for Intradermal Skin Test

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00853476
Recruitment Status : Completed
First Posted : March 2, 2009
Last Update Posted : February 18, 2011
Information provided by:
Chulalongkorn University

Brief Summary:
This study aims to compare skin reactivity results between morphine and histamine as a positive control agents in intradermal skin test.

Condition or disease
Intradermal Test

Detailed Description:
Histamine hydrochloride and different concentrations of morphine sulfate will be intradermally injected and wheal diameter size will be comparatively measured between 15-30 minutes' time points after the test.

Study Type : Observational
Actual Enrollment : 25 participants
Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: The Standard Concentration of Morphine as a Positive Control for Intradermal Skin Test
Study Start Date : March 2009
Primary Completion Date : October 2009
Study Completion Date : October 2009

Primary Outcome Measures :
  1. Wheal diameter from morphine skin test at different concentrations compared to standard histamine between 15-30 minutes after skin test [ Time Frame: 30 minutes ]

Secondary Outcome Measures :
  1. Side effects [ Time Frame: 24 hours ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Adult Healthy Volunteers

Inclusion Criteria:

  • age 18-60 years old

Exclusion Criteria:

  • immunodeficiency state
  • cancer
  • severe skin diseases
  • severe medical illnesses
  • malnutrition
  • uncontrolled asthma
  • pregnancy
  • received oral or systemic corticosteroid within 1 month before this study
  • receiving immunosuppressive agents
  • taken antihistamine within 3 days before this study
  • taking beta-blocker
  • previous history of immunotherapy
  • have hypersensitivity reaction to morphine/opiates

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00853476

Faculty of Medicine, Chulalongkorn University
Bangkok, Thailand, 10330
Sponsors and Collaborators
Chulalongkorn University
Principal Investigator: Jettanong Klaewsongkram, MD Chulalongkorn University

Additional Information:
Responsible Party: Jettanong Klaewsongkram, MD, Chulalongkorn University
ClinicalTrials.gov Identifier: NCT00853476     History of Changes
Other Study ID Numbers: Chula-ARC 001/09
First Posted: March 2, 2009    Key Record Dates
Last Update Posted: February 18, 2011
Last Verified: February 2011

Additional relevant MeSH terms:
Analgesics, Opioid
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents